Status and phase
Conditions
Treatments
About
This Randomized Controlled Trial was to clarity the clinical feasibility of PDOX results in guiding the drug use of interventional chemotherapy after primary liver cancer surgery.
Full description
Data of Patients who received PDOX after primary liver cancer radical reaction and received Transarterial Chemoembolization #will be collected
#excluding incomplete data. The primary endpoint was the one-year disease-free survival(DFS) rate #Secondary endpoint was the adverse event.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
90 participants in 2 patient groups
Loading...
Central trial contact
Mingxin Pan, Prof.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal